Abstract: To develop an effective method of bone augmentation for dental implants, particularly for patients with a scarce amount of bone, we introduced a new honeycomb-like -tricalcium phosphate (H--TCP) as a scaffold, whose unique geometrical properties induce bone formation along with vasculature. A total of six beagles from 6 to 7 years old were used for this study. Autologous bone marrow-derived mesenchymal cells (BMC) cultured with H--TCP were implanted around the dental implants, and healing was compared with conventional bone augmentation using autogenous bone. The 2-wall peri-implant defects were filled with the scaffold material pre-coated with BMP-2 and cultured with BMCs. Judging from the surface contact area between the bone and the implant, at 12 weeks the highest bone formation was found in the experimental group using the BMP-2 coated H--TCP with BMCs. This was significantly higher than the control H--TCP with BMP-2-coating but without BMC. It was noted that within the tunnels of the implanted H--TCP, one or two blood vessels with a diameter of 50-100 micro meter were generated in most cases after 2 weeks. These results suggested that the geometry of the honeycomb like -TCP with, gave advantages in terms of initial induction of blood vessel formation which is essential for bone augmentation.
Introduction
The severely resorbed maxillae or mandible often poses difficulties in placement of implants and the insufficient bone mass often does not permit the use of conventional implant surgery 1) . Historically, materials for bone regeneration have been obtained from autogenic or allogenic bone or bone-derived materials. Demineralized freeze-dried bone and other allogenic bone materials have an excellent ability to induce new bone formation. However, implanted materials derived from living organisms present risks such as infection, carcinogenesis due to latent pathogens, and allergy. The use of new artificial materials for bone regeneration can eliminate these risks however five factors must be taken into consideration 2, 3) . The pursuit of the optimal method for bone regeneration requires 1) cells, 2) matrices, 3) vasculature, 4) regulators and 5) mechanodynamics. Furthermore, effective artificial extracellular matrix (ECM) geometry is necessary as an element triggering them effectively. The superiority of honeycomb-like structures with numerous straight tun nels, 0.3-0.4 mm in d iameter, made from hydroxyapatite ceramics 4) and collagenous preparations 5) , led us to conclude that this is an ideal geometry for bone formation. It is well known that bone marrow stroma contains progenitor cells with osteogenic potential, generally referred to as mesenchymal stem cells or bone marrow derived mesenchymal cells (BMC) 6) . BMP-2 is known to be an essential factor for osteoblastic differentiation from undifferentiated mesenchymal cells (MC) 7) . Our previous studies have shown that these, when combined with BMP-2 hydroxyapatite carriers, are not only drug delivery systems (DDS) but also more importantly function as an artificial ECM, on which cells can undergo growth and the formation of different tissues: bone or cartilage, when implanted into rat skin. This was demonstrated clearly by Tsuruga et al. 9) who showed, by quantifying osteocalcin and alkaline phosphatase activities, that the osteo-inductive abilities of hydroxyapatite blocks with different tunnel sizes differed considerably and concluded that the optimal tunnel diameter for bone formation was 300-400 μm. Many other workers have recognized that the artificial ECM geometrical structure at the micron scale contributes to the differential expression of cellular functions in osteogenesis 10) . Recently, collagen and calcium phosphate compounds and nanomaterials that promote calcification have been developed, and their effects on the efficiency of osteogenesis reported 11, 12) .
However, the optimal geometries of these artificial ECM for bone induction have not been studied extensively. In parallel, biological preparations containing cytokines, such as PRP or enamel proteins have also been studied for local applications in experimental or practical use [13] [14] [15] . Above all, shown that BMP-2 is able to induce osteogenesis of MC with appropriate scaffolds, and is regarded as the most promising cytokine for clinical use in terms of the efficiency of osteogenesis.
On the basis of the above findings, we have devised a new artificial ECM consisting of honeycomb-like beta-tricalcium phosphate (H--TCP), predicting that the tunnel structure in this scaffold would guide the initial stages of bone formation in implant therapy, in which the use of MC in a large animal model constitutes the first step towards clinical applications.
Material and Methods

Animals
Six female Beagle dogs, each weighing from 10 to 12 kg, were used for this study. The animals were randomly allocated into 4 and 12 week groups with 3 dogs in each group. All surgical procedures and postoperative care of animals were carried out in accordance with the guidelines of the National Institutes of Health for care and use of animals. The study protocol was approved by the Animal Experimentation Committee of Showa University and the Researches Ethical Review Board of Matsumoto Dental University.
Preparations of BMSC
We used bone marrow mesenchymal cells (BMC) as for MC which were collected from femora by a modified version of a previously described method 16) (Fig. 1A) . Bone marrow needles (diameter 1.6 mm; Komet LLC, USA) inserted into the proximal and distal diaphyses of the femur were used for collection of bone marrow. The femoral bone cavity was perfused with 100 ml of phosphate-buffered saline (PBS) (0.01 M pH 7.2) containing 1.2U/ ml heparin sodium (Ajinomoto Co., Tokyo, Japan). Bone marrow fluid was collected from each animal into a separate tube, and centrifuged at 500 g for 5 min at room temperature. Precipitates were re-suspended and seeded in the same volume of Dulbeco's modified alpha-minimum essential medium ( -MEM; Gibco BRI., Gaithersburg, MD) containing 5% autologous serum, 50 U/ml penicillin, and 100 mg/ml streptomycin (Meiji Seika, Japan). Autologous serum was prepared according to the method of Stute et al. 17) . The medium in the flask was replaced every other day with the same volume of fresh medium. Two weeks later, adherent cells were collected and used for experiments as BMSC. Greater than 90% positivity for CD90 and CD105 was confirmed without CD14 or CD34 being detected among the collected cells by fluorescence activated cell sorting (FC500, Beckman, USA) as described previously (data not shown) 8) . As a parallel experiment to confirm the osteogenic potency of BMC, 5×10 3 cells/cm 2 were cultured in osteogenic medium (Lonza Walkersville Inc., MD, USA), then maintained according to the manufacturer's protocol. After the culture period, the cells were fixed and stained for alkaline phosphatase (APase) and calcification using Alizarin Red, by previously described methods 8) .
Preparation of artificial bone
Honeycomb-like beta-tricalcium phosphate (H--TCP) was produced following the method reported previously 3) . H--TCP discs (height: 1.0 mm, diameter: 3.0 mm, inside tunnel diameter: 300 m) were kindly donated by Pilot Corporation (Tokyo, Japan) for this study (Fig. 1B) .
Fifteen thousand cells/cm 2 of BMCs were combined with H--TCP in osteogenic induction medium using a centrifuge culture method for retaining and condensing BMCs into H--TCP for 12 hours in a 15 ml conical tube (Fig. 1C ). After combining, the H--TCP and BMCs complexes (H--TCP/BMC) were cultured with or without 100 ng/ml recombinant human BMP-2 (BMP-2; R&D Systems, Minneapolis, MN) for 24 hours at 5%CO 2 at 37 ºC until following implant surgery. Parallel culture was incubated for 7 days for verifying to APase activity of each dog's BMCs. APase activity was also determined biochemically after solubilization of the cells with 1.5 M Tris buffer containing 1% Triton X-100, as described previously 18) 5 mM p-nitrophenylphosphate (Sigma, St.
Louis, MO) was used as the substrate and activity was expressed as nano-mol of p-nitrophenol (p-NP) formed/min/mg protein assuming 1 A 410 = 64 nmol of product. The protein level was determined by Lowry protein assay (Bio-Rad Laboratories, Inc., Tokyo, Japan).
Surgical procedures
All mandibular premolars of dogs were extracted three months before the experiment under general anesthesia. One-wall bone defects (length 7 mm × height 5 mm) were prepared on each side of the mandibles, and Brånemark Mark III TiUnite (Nobelbiocare) implants (length 11.5 mm × diameter 3.75 mm) were placed into the center of each defect ( Fig 
Histological preparation
The animals were sacrificed under general anesthesia after a healing period of 4 and 12 weeks (n=3 dogs each), and the oral tissues were fixed using 10 % buffered formalin and dehydrated.
The specimens were embedded in Technovit 7200 resin to prepare undecalcified ground sections. The tissue samples were cut through the midaxial line of the implants in bucco-lingual orientation into slices of 200 m using a diamond-coated band saw. Three consecutive sections were obtained from each specimen and marked as sections1, 2, and 3. Each section was then trimmed to a final thickness of 3-10 m using an Exakt grinding machine assisted with mechanical digital micrometer (Exakt, Norderstedt, Germany). Each specimen was stained with 1% toluidine blue and von Kossa's stain for general histological observation.
Histomorphometric parameters were measured in the buccal and lingual dimension, the examiner was blinded to the respective therapy group. Relative bone-to-implant surface contact (%) in the area of the regenerated bone was calculated. The contact distance was estimated from the measurements obtained from the three pieces of specimens printed to 20 times of the three samples in each group on the buccal side and the lingual side. The contact distance with the implant was expressed at percentage of the surface length of the implant in the range "d" in Fig. 2C .
Statistical Analysis
Data for all of the implanted materials were expressed as the mean +/-standard error. Statistical analysis was performed using Fisher's PLSD test after ANOVA at each time point. P values less than 0.05 were considered significant. Calculations were performed with a Stat View 4.5 J program (Abacus Concepts, Inc., Berkeley, CA, USA).
Results
Osteoblastic differentiation of BMC
BMCs were cultured in osteoblast differentiation medium including BMP-2. They formed several nodules during days 7 to 10 of the culture (Fig. 3A) . APase activity was observed around day 10 (Fig. 3B) . Alizarin red stained calcified matrix was observed from days 17 to 21 (Fig. 3C) . No fibroblastic, adipogenic or chondrogenic differentiations were identified. These results suggested that BMCs were holding osteogenic potency during culture.
Osteogenic capacity of BMC in H--TCP culture
BMCs were colonized on H--TCP thickly in osteoblastic differentiation media with and without BMP-2 for transplantation (Fig. 3D) . APase positive BMCs were observed in abundant secreted extracellular matrix in a layer lining the H--TCP tunnel walls at day 7 of culture, enclosing a central channel (Fig. 3E) .
The results were similar with cells from all six dogs. APase activity of BMCs in H--TCP culture increased to 9 times of without (1.72) was extensively covered with new bone. In the H--TCP/BMC group (Fig. 4D, I ), although newly formed trabecular bone was seen in direct contact with the implant surface. The large amount of newly formed bone originating from the host bone that was direct contact for the implant surface appeared in the H--TCP/ BMC/BMP-2 group (Fig. 4E, J) , equivalent to that seen in other groups. The H--TCP/BMC/BMP-2 group, most of the implant surface was in contact with thickly formed new bone resembling that in the H--TCP/BMP-2 group.
Interestingly, blood vessels had formed in the newly synthesized bone in the tunnels of H--TCP at 4 weeks (Fig. 4K) . Osteoblastslined the surface of the H--TCP as on the marrow side of the cortical bone. Osteocytes were embedded in new bone.
Resorption of the H--TCP and newly formed bone by osteoclasts was also observed (Fig. 4L) .
Bone morphometry
Morphometric examination demonstrated that about 21 by BMP-2 (18.2) (Fig. 3F) .
Histological findings in the implant periphery
To analyze the ability of H--TCP in preclinical condition, almost a little new bone were formed in the H--TCP treated group in four weeks and 12 weeks (Fig. 4B, C, D, E, G, H, I , J) by alveolar bone around the implant peripherally than non-treated control group (Fig. 4A, F) . Effectively, new bone formation at the alveolar bone ridge and direct contact toward the implant was observed in these groups using H--TCP at 12 weeks more than 4 weeks after surgery (Fig. 4G, H, I, J) . In the H--TCP/BMP-2 group (Fig. 4C, H contact was seen in the bone defect area at 4 weeks after implantation. In contrast, the bone implant contact ratios at 12 weeks after implantation in the H--TCP/BMP-2 group were higher than those of the H--TCP group and the H--TCP/BMC group. The ratio in the H--TCP/BMC with BMP-2 group was significantly higher than that of the H--TCP/BMC group at 12 weeks after implantation (Fig. 5) .
Discussion
As new bone is formed during healing, it is important that the planned form is maintained by bone filling material. We attempted this study because there have been no reports of in vivo analysis of artificial bone biomaterial hybridized with osteoblasticphenotype promoted autologous MSC. We used BMCs, which retained multi-potency as MSC, and the efficiency of H--TCP as a carrier was examined. Three new steps in the method consisting of 1) pretreatment for osteoblastic differentiation of BMCs, 2) transplantation of autologous BMCs, and 3) H--TCP which has been previously shown to promote vascular induction are included in this experiment. The method provides five required components for tissue regeneration to ensure correct bone formation.
We showed that BMCs exhibited increased APase activity at days 7-14 following BMP-2 pretreatment in vitro (Fig. 3) . Additionally, the BMCs composites (H--TCP/BMC) expressed Runx2, APase, and osteocalcin genes when BMP-2 was present in the culture 6) . Then, they induced active bone formation, as evidenced by clear calcification in the diffusion chamber experiment. Together, these results and those of others have shown that BMCs were had differentiated to osteoblasts in vivo with pretreatment in osteoblastic differentiation medium including BMP-2 [19] [20] [21] [22] [23] . Usually, bone formation was dominant, and only a small amount of cartilage formation was observed. Chondrogenesis in an early stage of bone formation is commonly seen in fracture healing as endochondral ossification and even in the healing of Previous researchers have suggested that it is difficult to control the effect of BMP-2 by a carrier. Smeets et al. 25) reported that no significant differences in newly formed bone were found at the bone-implant interface when bone regeneration with or without BMP-2. The amounts of BMP-2 applied did not appear to enhance implant-osseointegration in large buccal defects. Jäger et al. 26) reported that BMP-2 enhances osteogenic differentiation of mesenchymal bone marrow cells in vitro within medium containing dexamethasone, ascorbic acid, and -glycerophosphate. BMP-2 was contained in the osteogenic differentiation culture medium in our experiment. As for our pretreatment period, it was synchronized to coincide with the BMP-2 signaling which is induced within 24-48 hours during osteoblastic differentiation. In the BMC hybrid group, bone formation potency was higher than in the other groups in the implant periphery (Figs. 4, 5) .
Botticelli et al. 27, 28) reported that the bone level was recovered when the alveolar bone defect was equal to or less than 2 mm. No matter how small a defect is, this suggests that space where a blood vessel and a cell can communicate is required. Kaigler et a l . 2 9 ) 
d e m o n s t r a t e d V E GF s c a ff o l d s c o u l d e n h a n c e neovascularization and bone regeneration in irradiated osseous
defects. Moreover, they showed that crosstalk dependent VEGF secretion was observed between osteoblasts and microvascular endothelial cells. Song et al. 30) reported that a balanced regulation of Id1 expression in VEGF-EPCs and BMP2-BMCs may be critical to cell-based and gene-based approaches for bone regeneration. Angiogenesis within the H--TCP tunnels was promoted in the presence of BMP according to our morphometrical analysis. Kilarski et al. 31) demonstrated that tension of the matrix and growth factors are necessary to form and maintain microvascular tissue. Zhou et al. 32) reported that construction of a vascularized tissue-engineered bone with mesenchymal stem cells and MSC-derived endothelial cells co-cultured in poroustricalcium phosphate ceramic induced repair of ulna bone defects in rabbit. As for our findings, the histology of the tissue surrounding the implants confirmed that maintenance by H--TCP without implant thread exposure was due to osteogenesis. H--TCP is pre-formed and is of a size that was easy to use, and we were able to easily apply it to the alveolar bone surface and cover the exposed implant in the defective part of the alveolar bone wall. As another benefit, H--TCP is not granular, so there was no need to use filling pressure to the focus and form a solid graft material. As a result, postoperative morphology changes and degradation of the site due to particle rearrangements were not seen (Fig. 4B, C, D an extraction tooth socket 18, 24) . However, BMC proliferated along the tunnel wall, then bone tissue was generated in the transplanted site of H--TCP/BMC with BMP-2 (Figs. 3, 4, 5 ). There was no chondrogenesis or adipogenesis observed in H--TCP, H--TCP/ BMC or H--TCP/BMC/ BMP-2 grafted sites.
Tatsuo Shirota et al.: Honeycomb β-TCP Induced Bone Around Dental Implants by Angiogenesis blood vessel with a diameter of 50-100 mm formed lengthwise in the center of the H--TCP tunnels (Fig. 4K) . Most blood vessels were formed on the gingival side possibly because the vascular space was wider in the gingival side of H--TCP and narrow on the implant side. These results clearly confirm that bone formation is highly dependent on the geometry of the carrier, which provides favorable structural factors for vascularization during proliferation and maturation of BMC in the tunnel wall of H--TCP. The key to success of the implant therapy is to maintain newly formed bone tissue. When resorption of the biomaterial occurs markedly earlier than osteogenesis, a desirable bone form is not maintained.
Normal bone maintenance requires not only osteogenesis by osteoblasts but also the coupling of osteoblasts and osteoclasts [33] [34] [35] . Therefore, ideally a bone biomaterial should promote synchronous osteogenesis by osteoblasts and resorption by osteoclasts. The resorption of -TCP by both macrophages and osteoclasts has been reported 36) and in fact our tissues also showed evidence of direct resorption by osteoclasts of H--TCP (Fig. 4L ).
To maintain bone quality, it may be necessary for there to be a temporal difference between new bone formation and resorption of the carrier, as may be achieved, for example 37) , using mixed biomaterial, hydroxyapatite (HA), and -TCP. Tazaki et al. 38) suggested that the resorbable -TCP block may be an effective with that by HA has been reported 39) . In addition, osteoclasts formed from monocyte lineage cells with TCP had less TRAP activity than HA, but the pits formed were deeper 40) . -TCP particles might lead to lower rates of monocyte linage cell differentiation and osteoclastogenesis and subsequent particleinduced inflammation and bone resorption. Therefore, resorption of -TCP by multinuclear osteoclast-like cells occurring with rapid osteogenesis by the vascular induction approach indicated in this study and the normal remodeling of the newly formed bone are consistent with these previous in vivo findings 3) . Together, these results suggested that blood vessels were rapidly induced from surrounding tissue by a continuous 300 micro meter diameter tunnel of TCP, and osteogenesis occurred normally, and this underlines the importance of the five factors for bone regeneration.
One of the major challenges to be faced in the routine clinical use of carriers in engineered bone tissues is related to their manufacturing process, which, at present, is costly, impractical, and insufficiently standardized. It is necessary for safety reasons to use automated equipment and a highly controlled culture system to reproducibly and safely culture cells for transplantation 41, 42) .
Therefore, if the clinical studies using the Cell Processing Center based on good clinical practice (GCP) is utilized effectively, this system is practical in terms of safety, and is economic for osteogenesis treatment.
We concluded that differentiation to osteoblasts by BMCs and osteogenesis were demonstrated in vivo and in vitro with H--TCP, which was shown to have the geometric properties necessary to permit angiogenesis. The results indicated that the H--TCP/ BMC hybrid may reinforce bone formation in alveolar bone periimplant defects. Moreover, pre-treatment of BMP-2 may induce osteoblastic differentiation of BMC with H--TCP in vivo. Matrixlike structures were observed when tunnel of H--TCP were filled with BMCs. In the experimental group transplanted with autologous cells newly formed bone was seen in contact with a wide area of the implant surface. Osteogenesis accompanied by excellent angiogenesis was observed in H--TCP tunnel. These results indicated that tricalcium phosphate scaffolds with vasculature-inducing geometry gave advantages in terms of duration and quantity of regeneration in peri-implant bone defects.
